title: Cardiac effects of short course dexamethasone in preterm infants.
abstract: OBJECTIVE
  To examine the incidence and natural history of left ventricular hypertrophy (LVH) associated with the shorter 2-3 week course of dexamethasone, now more usual, for chronic lung disease.
  
  
  METHODS
  Thirty one infants, gestational age 23-34 (median 26) weeks, birthweight 500-2054 (median 815)g, received dexamethasone, starting at 0.4-0.6 mg/kg/day, at a median of 11 days of age (range 2-34), weaning over a period of 2-3 weeks. Eighteen preterm neonates were studied as controls over a similar time period. Serial echocardiographic measurements of end diastolic interventricular septum (IVSd) and left ventricular posterior wall (LVPWd) thicknesses were taken before, and up to 48 days after, starting dexamethasone. Maximum Doppler blood flow velocities from the left ventricular outflow tract (LVOT) were measured.
  
  
  RESULTS
  Left ventricular hypertrophy (LVH) occurred in 29 babies (94%). Median hypertrophy of the IVSd in those receiving dexamethasone was 67% and LVPWd 56% of baseline measurements, significantly greater than control infants (p < 0.001). LVH appeared by a median of three days, peaking by a median of 10 days. All resolved by a median of 27 days. LVOT obstruction was not seen. There was no significant correlation with birthweight, gestation, blood pressure, or glucose tolerance.
  
  
  CONCLUSIONS
  LVH developed in almost all preterm neonates receiving a 2-3 week course of dexamethasone, but was of little clinical importance and always resolved. Echocardiography is probably not required routinely in infants receiving such short course dexamethasone for chronic lung disease.
authors.affiliation: Peter Congden Neonatal Intensive Care Unit, Leeds General Infirmary.
authors.forename: R
authors.initials: R
authors.lastname: Skelton
authors.forename: A B
authors.initials: AB
authors.lastname: Gill
authors.forename: J M
authors.initials: JM
authors.lastname: Parsons
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002908:Chronic Disease; D003907:Dexamethasone / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004452:Echocardiography; D005260:Female; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000139:chemically induced* / Q000503:physiopathology; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000503:physiopathology; D008171:Lung Diseases / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D018709:Statistics, Nonparametric; D013997:Time Factors
chemical_list: D000893:Anti-Inflammatory Agents; D003907:Dexamethasone